Recombinant
RabMAb

Anti-Caveolin-3 antibody [EPR18975] (ab182739)

Overview

  • Product name
    Anti-Caveolin-3 antibody [EPR18975]
    See all Caveolin-3 primary antibodies
  • Description
    Rabbit monoclonal [EPR18975] to Caveolin-3
  • Tested applications
    Suitable for: WB, IP, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human Caveolin-3 aa 1-100. The exact sequence is proprietary.
    Database link: P56539

  • Positive control
    • WB: Human fetal heart lysate; Human skeletal muscle lysate. IHC-P: Human skeletal muscle and cardiac muscle tissues. IP: Human fetal heart whole cell lysate.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab182739 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 17 kDa (predicted molecular weight: 17 kDa).
IP 1/20.
IHC-P 1/200. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Target

  • Function
    May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress.
  • Tissue specificity
    Expressed predominantly in muscle.
  • Involvement in disease
    Defects in CAV3 are the cause of limb-girdle muscular dystrophy type 1C (LGMD1C) [MIM:607801]. LGMD1C is a myopathy characterized by calf hypertrophy and mild to moderate proximal muscle weakness. LGMD1C inheritance can be autosomal dominant or recessive.
    Defects in CAV3 are a cause of hyperCKmia (HYPCK) [MIM:123320]. It is a disease characterized by persistent elevated levels of serum creatine kinase without muscle weakness.
    Defects in CAV3 are a cause of rippling muscle disease (RMD) [MIM:606072]. RMD is a rare disorder characterized by mechanically triggered contractions of skeletal muscle. In RMD, mechanical stimulation leads to electrically silent muscle contractions that spread to neighboring fibers that cause visible ripples to move over the muscle.
    Defects in CAV3 are a cause of cardiomyopathy familial hypertrophic (CMH) [MIM:192600]; also designated FHC or HCM. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in CAV3 are the cause of long QT syndrome type 9 (LQT9) [MIM:611818]. Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to excercise or emotional stress. They can present with a sentinel event of sudden cardiac death in infancy.
    Defects in CAV3 can be a cause of sudden infant death syndrome (SIDS) [MIM:272120]. SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive. Long QT syndromes-associated mutations can be responsible for some SIDS cases.
  • Sequence similarities
    Belongs to the caveolin family.
  • Cellular localization
    Golgi apparatus membrane. Cell membrane. Membrane > caveola. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
  • Information by UniProt
  • Database links
  • Alternative names
    • CAV3 antibody
    • CAV3_HUMAN antibody
    • Caveolin 3 antibody
    • Caveolin-3 antibody
    • LGMD1C antibody
    • LQT9 antibody
    • M-caveolin antibody
    • MGC126100 antibody
    • MGC126101 antibody
    • MGC126129 antibody
    • OTTHUMP00000115603 antibody
    • OTTHUMP00000207105 antibody
    • VIP 21 antibody
    • VIP21 antibody
    see all

Images

  • All lanes : Anti-Caveolin-3 antibody [EPR18975] (ab182739) at 1/1000 dilution

    Lane 1 : Human fetal liver lysate
    Lane 2 : Human fetal heart lysate
    Lane 3 : Human fetal kidney lysate
    Lane 4 : Human fetal spleen lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size : 17 kDa
    Observed band size : 17 kDa


    Exposure time : 5 seconds

    Blocking/Dilution buffer: 5% NFDM/TBST.

    Expressed predominantly in muscle.

  • All lanes : Anti-Caveolin-3 antibody [EPR18975] (ab182739) at 1/1000 dilution

    Lane 1 : Human skeletal muscle lysate
    Lane 2 : Human fetal lung lysate
    Lane 3 : HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate
    Lane 4 : A-673 (Human muscle Ewing's Sarcoma cell line) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size : 17 kDa
    Observed band size : 17 kDa


    Exposure time : 30 seconds

    Blocking/Dilution buffer: 5% NFDM/TBST.

    Expressed predominantly in muscle.

  • Immunohistochemical analysis of paraffin-embedded Human skeletal muscle tissue labeling Caveolin-3 with ab182739 at 1/200 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Membrane staining on Human skeletal muscle was observed. Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human cardiac muscle tissue labeling Caveolin-3 with ab182739 at 1/200 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Membrane staining on Human cardiac muscle was observed. Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Caveolin-3 with ab182739 at 1/200 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Negative on Human liver. Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human hepatocellular carcinoma tissue labeling Caveolin-3 with ab182739 at 1/200 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Negative on Human hepatocellular carcinoma. Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

     

  • Caveolin-3 was immunoprecipitated from 1mg of Human fetal heart whole cell lysate with ab182739 at 1/20 dilution. Western blot was performed from the immunoprecipitate using ab182739 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

    Lane 1: Human fetal heart whole cell lysate 10ug (Input). 

    Lane 2: ab182739 IP in Human fetal heart whole cell lysate. 

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab182739 in Human fetal heart whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.
    Exposure time: 10 seconds.

References

ab182739 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab182739.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up